Patients with high MLL2 expression had significantly poorer overall survival than those with low MLL2 expression, suggesting that high MLL2 expression may serve as a predictive marker of poor prognosis and may be a potential therapeutic target in ESCC. This evidence concerns the gene KMT2D and esophageal squamous cell carcinoma.